The Product Quality Review (PQR) is the periodic quality review that every pharmaceutical manufacturing site must perform, normally annually, on all the authorised medicinal products it manufactures. It is not a paperwork exercise: it is the tool through which the Pharmaceutical Quality System demonstrates that processes are consistent, that starting material and finished product specifications remain appropriate, and that trends are caught before they become deviations. In this article we look at what Chapter 1 of the EU GMP requires, how it compares with the FDA Annual Product Review, how to structure a PQR report that is defensible in audit, and which mistakes to avoid.
Product Quality Review: what it is and who requires it
The main regulatory reference in Europe is paragraph 1.10 of Chapter 1 of EudraLex Volume 4 (Part I), which requires "regular periodic or rolling quality reviews of all authorised medicinal products", normally conducted and documented annually, taking into account previous reviews. The stated objective is threefold: verifying the consistency of the existing process, the appropriateness of current specifications for starting materials and finished product, and highlighting trends that call for product or process improvements.
The requirement is not only European. For APIs, ICH Q7 (section 2.5) requires regular quality reviews with the same objective of verifying process consistency, normally documented annually. In the United States, 21 CFR 211.180(e) requires the evaluation, at least annually, of the quality standards of each drug product: the so-called Annual Product Review (APR). Finally, PIC/S mirrors in its GMP Guide (PE 009, Part I) a text aligned with EU Chapter 1, making the PQR a de facto global expectation.
Responsibility for the final assessment lies with the manufacturer, but where the Marketing Authorisation Holder (MAH) is not the manufacturer, a technical agreement must define the respective roles in preparing and assessing the review. The manufacturer, together with the MAH where applicable, must evaluate the results and decide whether CAPA or revalidation is needed, documenting the rationale and completing the actions in a timely and effective manner.
The 12 minimum contents required by paragraph 1.10
Chapter 1 explicitly lists what the review must include "at least". It is the natural checklist for building your company template:
- A review of starting materials and packaging materials, especially those from new sources, including the supply chain traceability of active substances;
- A review of critical in-process controls and finished product results;
- All batches that failed to meet established specifications and their investigations;
- All significant deviations and non-conformances, with investigations and an assessment of CAPA effectiveness;
- Changes made to processes or analytical methods;
- Marketing Authorisation variations submitted, granted or refused (including third-country dossiers);
- Results of the stability monitoring programme and any adverse trends;
- Quality-related returns, complaints and recalls, with the related investigations;
- Adequacy of previous corrective actions on process or equipment;
- Post-marketing commitments for new authorisations and variations;
- Qualification status of relevant equipment and utilities (HVAC, water, compressed gases);
- Up-to-date contractual/technical agreements.
The paragraph also allows reviews to be grouped by product type (e.g. solid dosage forms, liquids, sterile products), provided the choice is scientifically justified.
If you deal with PQR, deviations and trends once a year but want to think about them all year round, subscribe to The Pragmatic GMP, GuideGxP's free weekly newsletter: every week one pharmaceutical quality topic, covered from a hands-on, audit-ready perspective.
EU PQR and FDA APR: the differences that matter
Anyone working for multiple markets needs to harmonise three similar but not identical requirements. The table summarises the key points:
| Aspect | EU GMP Ch. 1, §1.10 (PQR) | FDA 21 CFR 211.180(e) (APR) | ICH Q7 §2.5 (APIs) |
|---|---|---|---|
| Frequency | Periodic or rolling, normally annual | At least annual | Normally annual |
| Batch scope | All batches, including export-only | A representative number of batches, approved and rejected | API batches, focused on process consistency |
| Listed contents | 12 explicit minimum items | Written procedure; batches, complaints, recalls, returns and §211.192 investigations | 7 areas (critical IPC, OOS, deviations, changes, stability, complaints/returns/recalls, CAPA) |
| Expected outcome | Assessment with the MAH, documented CAPA or revalidation | Evaluation of quality standards and need for changes | Assessment of the need for CAPA or revalidation |
The most frequently cited practical difference concerns scope: the EU approach requires the review of all batches and 12 explicit areas, while the FDA text is more concise and leaves the detail to the company procedure. A single template built on the EU requirements generally also covers FDA and PIC/S expectations: it is the most efficient strategy for multi-market sites.
Example structure of a PQR report
An effective report is not a collection of attachments, but a document that tells the product's story over the year. A proven structure:
- Header and scope: product, strengths and presentations covered, review period, reference to the company SOP;
- Production data: batches manufactured, approved, rejected, reworked, with yields and comparison with the previous year;
- Statistical analysis of critical data: trends of in-process controls and release results (control charts, capability where appropriate);
- One section for each of the 12 items of §1.10: even just to state "no events in the period", so that absence is a data point and not an omission;
- Conclusions and validation status assessment: is the process in control? Do the specifications remain appropriate?
- CAPA and recommendations: actions with owner and due date, plus verification of the actions recommended in the previous review.
Typical findings in audits
- Chronically late PQRs: reviews signed 8-10 months after the end of the period lose all value as a control tool;
- Copy-paste from the previous year: identical conclusions year after year despite different deviations and OOS results;
- Data without analysis: tables of results with no trend analysis or statistical evaluation, when §1.10 specifically asks to highlight trends;
- No link to QRM: adverse trends detected but never translated into risk assessments or tracked CAPA;
- Forgetting export batches and technical agreements: two explicit items of §1.10 often missing from outdated templates.
GuideGxP recommendation
Treat the PQR as a continuous process, not a year-end formality: collect the data for each section month by month (deviations, changes, stability, complaints), set an internal issuance deadline in your SOP (for example 90 days from the end of the period) and have the report approved by QA with visibility to the QP, who bases part of their batch release confidence on the PQR. A template aligned with the 12 items of §1.10, with a "no events" line where applicable, drastically reduces drafting time and inspection findings.
The PQR is one of the key processes a QA Manager must master: for complete operational support on this and the other quality system processes, take a look at GuideGxP's Operational Guide to the QA Manager Role in the Pharmaceutical Industry, designed to be defensible in audit from day one.
